Serum FGF23 levels were found to be significantly greater in the AIS group than in the control group (525.14 ± 167.40 pg./mL vs. 338.62 ± 161.71 pg./mL, <i>p</i> < 0.05). The gene discussed is FGF23; the disease is androgen insensitivity syndrome.